Research Article
Survival Benefit of Intervention Treatment in Advanced Anaplastic Thyroid Cancer
| Characteristic | N (%) |
| Gender | | Female | 79 (65.3) | Male | 42 (34.7) |
| Age (years) | | ≤40 | 3 (2.5) | 41–50 | 6 (4.9) | 51–60 | 23 (19.0) | 61–70 | 49 (40.5) | ≥70 | 40 (33.1) |
| Underlying disease | | No/Unknown | 88 (72.7) | Diabetes mellitus | 19 (15.7) | Hypertension | 17 (14.1) | Dyslipidemia | 3 (2.5) | Other | 15 (12.4) |
| Thyroid function test | | Hypothyroid | 8 (6.6) | Euthyroid | 17 (14.1) | Hyperthyroid | 3 (2.5) | Unknown | 93 (76.9) |
| WBC (cells/ml3) | | ≥10,000 | 48 (39.7) | <10,000 | 31 (25.6) | Unknown | 42 (34.7) |
| Tumor size (cm) | | <5 | 6 (4.9) | ≥5 | 88 (72.7) | Unknown | 27 (22.3) | Extrathyroid invasion involved vital structures | 14 (11.6) |
| Cervical lymph node metastasis | | No/Unknown | 69 (57.0) | Unilateral single | 24 (19.8) | Unilateral multiple | 18 (14.9) | Bilateral | 10 (8.3) |
| Distance metastasis | | No/Unknown | 89 (71.8) | Lung | 28 (22.6) | Bone | 5 (4.0) | Liver | 2 (1.6) |
| Staging | | IVa | 37 (30.6) | IVb | 39 (32.2) | IVc | 29 (23.9) | Unknown | 16 (13.2) |
| Treatment | | Supportive treatment | 37 (30.6) | Palliative radiation | 12 (9.9) | Surgery alone | 29 (23.9) | Chemoradiation | 9 (7.4) | Surgery combined radiation | 13 (10.7) | Surgery combined chemoradiation | 5 (4.1) | Unknown | 16 (13.2) |
|
|